Use of avermectin derivative for increasing bioavailability and efficacy of macrocylic lactones

US11130776B2 · kind B2 · utility

Assignees

• INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION L'ENVIRONNEMENT · FR
• The Royal Institution for the Advancement of Learning/McGill University · CA

Inventors

• Anne Lespine · Toulouse, FR
• Roger Prichard · Toulouse, FR
• Cecile Menez · Toulouse, FR

Key dates

• Filing date: Oct 18, 2012
• Grant date: Sep 28, 2021
• Expiry date: Oct 18, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D493/20
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to the use of avermectin derivative as a drug for the treatment of parasitic infections. The avermectin derivative is represented by the formula (I) wherein: (i) R1 is chosen from the group constituted of —CH(CH3)2, —CH(CH3)CH2CH3, or cyclohexyle, (ii) X represents —CH2—CH2—, or —CH═CH—, (iii) R2 is chosen from the group constituted of or —OH group, (iv) R3 is OH or NOH, (v) represents a single bond when R3 is OH, or a double bond when R3 is NOH, as an inhibitor of a membrane-bound protein which transports exogenous compounds out of target cells.